| abstract |
FIELD: pharmaceutics. n SUBSTANCE: invention relates to pharmaceutical industry and medicine and represents a drug of anti-tuberculosis action in the form of a lyophilisate for oral application weight 2.0±0.20 g, containing D-cycloserine 12.5±1.25 wt%, polymer PLGA 50/50 50±5.0 wt%, polyvinyl alcohol 12.5±1.25 wt% and D-mannitol 25±2.5 wt%, with content of D-cycloserine from 0.225 to 0.275 g, which when diluted with water in amount of 100±10 ml forms a suspension of particles with size of not more than 800 nm, components of not less than 90 %. n EFFECT: invention provides high stability under conditions of long-term storage at temperature 5±3 °C for 18 months and accelerated storage at temperature 25±2 °C for 184 days, high bioavailability, including high tissue bioavailability in target organs of the infectious process, and low toxicity, neurotoxicity. n 6 cl, 3 ex, 5 tbl |